drugset / Trial / NCT06881992
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
NaSingle-groupOpen-labelTreatment
Summary
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Timeline
- Start
- 2025-04-16
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ersodetug | Monoclonal antibody | 9 mg/kg | — |